Refractory Anemia With Excess Blasts in Transformation Recruiting Phase 1 Trials for Azacitidine (DB00928)

Also known as: Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / Refractory anaemia with excess blasts in transformation / Myelodysplastic syndrome transformation

IndicationStatusPhase
DBCOND0028567 (Refractory Anemia With Excess Blasts in Transformation)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02553941Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic SyndromeTreatment